| |
|
|
|
|
| |
 |
|
| Compound |
Target |
Indication (Combination) |
Stage of Development |
Partner |
| HGS1029 |
Inhibitor of Apoptosis Proteins (IAPs) |
Solid Tumors |
Phase I |
 |
|
| IAP Inhibitors |
Inhibitor of Apoptosis Proteins (IAPs) |
Inflammation/autoimmune |
Optimized Lead Compounds |
|
 |
| Tyrosine Kinase Inhibitors |
• BTK
•
FMS |
Inflammation/autoimmune, Oncology |
Early Lead Compounds |
|
|
| HSP90 Inhibitors |
HSP90 |
Fungal Infections, CNS, Inflammation, Oncology |
Early Lead Compounds |
|
|
|
|
| |
|
|
|
|
|
